PND5 Alzheimer's Disease Caregiver Burden in Japan and the 5 E.U  by Gupta, S. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 7 1 9 – A 8 1 3  A809
pitalisation data from 2,074 patients with PD who were recruited into the PD 
MED trial from Nov 2000 to Dec 2009 and followed up for ten years. PD MED is a 
large-scale, “real-life” randomised controlled trial comparing the effectiveness and 
cost-effectiveness of PD medications. Patients’ demographic characteristics, dis-
ease severity, reasons and duration of hospitalisation were analysed. Reasons for 
hospitalisations were coded based on the International Classification of Disease 
(ICD-10). Results: Of 2,074 patients, at randomisation, median age was 72 years 
(IQR 66-77), mean duration with diagnosed PD was 2.8 years (median 2, IQR 1-3) and 
median Hoehn &Yahr score was 2 (IQR 1.5-2.5). Until Oct 2011, 29% (597/2074) of 
patients had a total of 941 hospitalisation records. Mean length of stay was 21days 
(median 9, IQR 3-24). Hospitalisation reasons were classified into 11 categories of 
PD related conditions and 15 PD unrelated categories. 64.1% of the hospitalisation 
records can be associated with PD. Main reasons for hospitalisation were: infec-
tions including pneumonia and urinary tract infection (18.4%), falls and fractures 
and other injuries (15.3%), cardiovascular and circulatory disorders (8.7%), central 
nervous system and disorders of sense organs (8.2%), gastrointestinal disorders 
(8.0%), and mental health disorders (6.9%). ConClusions: PD related conditions 
have a significant and broad ranging specialty impact on hospitalisation rates 
and associated health care costs are substantial. This paper provides economic 
justification for investing in interventions that manage infection and prevent 
falls in people with PD.
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objeCtives: Alzheimer’s disease (AD) is a chronic and progressive disease that 
is a significant burden on caregivers. Research indicates AD caregiver burden 
on health status; but there is limited research on caregiver burden in Japan. The 
objectives of this study were to examine Japan AD caregiver burden vs. Japan non-
caregivers and 5E.U. AD caregivers. Methods: Data were obtained from the 2012 
Japan (N= 30,000) National Health and Wellness Survey (NHWS) and 2013 5E.U. (UK, 
Germany, France, Italy, Spain; N= 62,000) NHWS, administered online to a representa-
tive adult sample (18+ years). Respondents reported on health status (SF-36v2), 
activity impairment, health care utilization in the past six months and caregiver 
responsibilities. Multivariable regressions, adjusting for demographics and health 
history variables to explore differences between Japan AD caregivers (n= 714) vs. 
Japan non-caregivers (n= 27,702) and 5E.U. AD caregivers (n= 1,239). Results: Japan 
AD caregivers were older and reported more depression symptoms than Japan non-
caregivers (p< 0.05). Japan AD vs. 5E.U. AD caregivers were older and more educated 
(p< 0.05). After adjustments, Japan AD caregivers had lower health status (p< 0.001), 
higher health care utilization, and greater activity impairment (p< 0.001) than Japan 
non-caregivers. Japan AD vs. 5E.U. AD caregivers had better mental (45.7 vs. 43.8, 
p< 0.001) and physical (51.0 vs. 50.0, p= 0.021) health status, marginally less activity 
impairment (24.5% vs. 27.1%, p= 0.070), but more health care provider visits (7.6 vs. 
5.4, p< 0.001) and hospitalizations (p< 0.001). Japan AD caregivers vs. 5E.U. caregivers 
were less likely to make treatment decisions and manage finances for AD relative 
(p< 0.001), were marginally less involved in helping with daily activities (transporta-
tion, meals, shopping, p= 0.054), but no difference was found on bathing/grooming 
involvement. ConClusions: Japan AD caregivers report more burden including 
more depression symptoms than Japan non-caregivers. Japan AD caregivers report 
greater health care utilization than 5E.U. AD caregivers, but report better health 
status, and less involvement in treatment and finance decisions.
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objeCtives: Multiple Sclerosis (MS) is a chronic disease which results in increasing 
disability over time. The Australian Multiple Sclerosis Longitudinal Study (AMSLS) 
is an ongoing study that collects information on around 3,100 volunteers with MS 
from all States and Territories in Australia. The WHO quality of life assessment 
instrument (WHOQOL-100) was collected as well as the following Patient Reported 
Outcome (PRO) measures; MS Self-Efficacy Scale, Perceived Stress Scale, Geriatric 
Depression Scale – short version (GDP-5), Social Support Scale, Therapeutic Self-Care 
Scale, and the Depression Anxiety and Stress Scale (DASS). In this analysis, we quan-
tified the difference in utility, stress, depression and social support needs between 
disease severities in subjects with MS. Methods: Data from the WHOQOL-100 
were collected in 2008. The utility score was calculated by mapping five questions 
from the WHOQOL-100 to the EQ-5D descriptive system as described by Al-Ruzzeh 
et al (2008). The UK TTO value set (utility weights) were applied to each of the lev-
els in each dimension. Disease severity was based on the self reported Disease 
Steps Scale. Results: A total sample of 2139 subjects provided evaluable data; 
a response rate of approximately 70%. Overall average QOL as measured by the 
WHOQOL-100 was 13.7 (95%CI: 13.5 to 13.8) out of a maximum value of 20, ranging 
from 11.8 (95%CI: 11.4 to 12.2) in severe disease to 15.2 (95%CI: 15.0 to 15.4) when 
mild. The utility score for all people with MS was 0.65 (95%CI: 0.64 to 0.67). The 
utility decreased with increasing disease severity with values of 0.80 (95%CI: 0.78 
to 0.81), 0.60 (95%CI: 0.58 to 0.61) and 0.42 (95%CI: 0.39 to 0.46) for mild, moderate 
and severe disease, respectively. The other instruments on the whole followed this 
trend. ConClusions: Higher disease severity in subjects with MS is associated 
with lower utility and QOL and worse outcomes in general.
outcomes, and study designs). Results: A review of the clinical efficacy of ivacaftor, 
its comparative clinical efficacy compared with dornase alfa, and a review of the 
cost-effectiveness of ivacaftor will help to inform decisions about the treatment of 
patients with CF. Four studies were presented as evidence of the benefit of ivacaftor 
in CF. Two pivotal trials STRIVE and ENVISION, one open label extension study, 
PERSIST, for patients in STRIVE and ENVISION and a final study in different patient 
group, DISCOVER, in patients who are homozygous for the F508del mutation. The 
percent predicted forced expiratory volume in 1 second (FEV1) was the primary 
outcome measure for the two phase III clinical trials. The review group noted the 
absence of long term efficacy data particularly in relation to the benefit of ivacaftor 
in maintaining percent predicted FEV1 and reducing pulmonary exacerbations and 
the resultant impact on survival rates. The analysis for this extrapolation is based on 
a number of prediction models that have been published. The disease progression 
model predicts that the median survival for a patient treated with ivacaftor will 
be 29.2 years longer as a consequence of taking the drug. ConClusions: Whilst 
ivacaftor may represent an innovation for the treatment of patients with cystic 
fibrosis there are significant uncertainties, including the absence of long term health 
outcome data.
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objeCtives: To determine the trend of drug utilization for Alzheimer’s disease 
during 2009 and 2013. Methods: Prescription data of outpatients with Alzheimer’s 
disease in 2009 – 2013 was extracted from the medical care database of the hospital. 
Quantities and costs of the prescribed drugs were examined using defined daily dose 
(DDD) for comparisons. Results: Number of patients was rather the same number 
every year ranging from 1,507 to 1,631 patients. For donepezil and memantine, 
number of DDD per year was increased every year ranging from 7.3–10.0 % to 1.6-
14.7% compared to the previous year, respectively. The increasing trends were not 
found in prescribing of rivastigmine, except for the dramatically increase (34.0%) 
in 2013. Galantamine was prescribed less in 2010 and 2013 accounted for -9.2 and 
-18.2%, respectively. Cost of drug use in Alzheimer’s disease was $3,211,269 in 2009 
and $3,228,454 in 2013 with an increasingly trend. ConClusions: The overall drug 
use in Alzheimer’s disease seems to be a heavy burden of the hospital every year. 
The rational drug use should be confirmed to make sure to guarantee appropriate 
use of drug without overusage.
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objeCtives: The purpose of this study was to review cost-effectiveness models in 
multiple sclerosis (MS) to identify accepted methods, key challenges, and best prac-
tices.  Methods: We searched MEDLINE, Embase, the Health Economics Evaluation 
Database (HEED), the Cochrane library, and recent HTA agencies’ (NICE and SMC) deci-
sions  for studies published prior to March 7, 2014. Following duplicate removal, 100 
studies were identified. Studies were excluded if they did not estimate cost-effective-
ness in MS, were duplicates, or weren’t published in English, resulting in a total of 26 
studies sourced. A data extraction form was developed to capture information about 
model characteristics, patient natural history progression, utility estimates, and the 
author’s comments on the modelling methods. Results: All studies were published 
after 2000, with most focused on first-line USA and EU patient populations. The major-
ity of models utilised a cohort Markov model approach, with health states defined by 
patient expanded disability status scale (EDSS) scores. Health states included either 
individual or aggregate EDSS scores (0-9.5) for relapsing-remitting MS (RRMS) and sec-
ondary progressive MS (SPMS), as well as a death state. Transition probabilities were 
sourced from trial data for low score EDSS states, while transitions for higher score 
EDSS states were sourced from a longitudinal study of Canadian MS patients, due 
to insufficient clinical trial data for patients with advanced disease. Key challenges 
identified in recent HTA decisions include modelling EDSS score improvement early 
in disease natural history, patients’ initial distributions across EDSS states, extended 
benefits of therapy, and patient treatment adherence. ConClusions: Established 
modelling best practice in MS utilises a cohort Markov model approach with health 
states simulating patient populations via EDSS scores in RRMS and SPMS. Future 
studies and HTA submissions should focus on more accurately reflecting patient 
natural history in the early stages of disease.
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objeCtives: Reasons for hospitalisations in people with Parkinson’s Disease 
(PD) are broad ranging and costly, however detailed analysis of hospitalisations 
in a large, representative group of PD patients is lacking. This study aimed to 
explore the reasons for, resource use and associated cost of hospital treatment 
in participants in the PD MED trial. Methods: We retrospectively reviewed hos-
